Humana (NYSE:HUM) Price Target Raised to $325.00

Humana (NYSE:HUM - Get Free Report) had its price objective boosted by stock analysts at Truist Financial from $290.00 to $325.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a "hold" rating on the insurance provider's stock. Truist Financial's price objective indicates a potential upside of 14.56% from the stock's current price.

Several other equities analysts also recently issued reports on the stock. Royal Bank of Canada restated an "outperform" rating and issued a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Piper Sandler raised their price target on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 15th. StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a research note on Monday, April 7th. Guggenheim started coverage on shares of Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 target price on the stock. Finally, Barclays lifted their price objective on shares of Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a research note on Thursday, February 13th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Humana presently has an average rating of "Hold" and an average target price of $284.90.

Remove Ads

Humana Stock Down 1.1 %

Shares of HUM stock traded down $3.09 during trading hours on Friday, reaching $283.69. 475,876 shares of the stock were exchanged, compared to its average volume of 1,746,125. Humana has a 12-month low of $213.31 and a 12-month high of $406.46. The business's fifty day moving average is $265.57 and its two-hundred day moving average is $270.22. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $34.24 billion, a P/E ratio of 28.51, a P/E/G ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts expect that Humana will post 16.47 EPS for the current fiscal year.

Institutional Trading of Humana

Several large investors have recently bought and sold shares of HUM. HighTower Advisors LLC increased its holdings in Humana by 2.1% during the 3rd quarter. HighTower Advisors LLC now owns 8,992 shares of the insurance provider's stock valued at $2,852,000 after acquiring an additional 187 shares in the last quarter. MML Investors Services LLC increased its stake in shares of Humana by 15.6% during the 3rd quarter. MML Investors Services LLC now owns 4,737 shares of the insurance provider's stock worth $1,500,000 after purchasing an additional 638 shares in the last quarter. Coldstream Capital Management Inc. raised its position in shares of Humana by 27.3% during the 3rd quarter. Coldstream Capital Management Inc. now owns 3,318 shares of the insurance provider's stock worth $1,032,000 after purchasing an additional 712 shares during the last quarter. Toronto Dominion Bank lifted its stake in Humana by 1.3% in the 3rd quarter. Toronto Dominion Bank now owns 59,992 shares of the insurance provider's stock valued at $19,002,000 after buying an additional 754 shares in the last quarter. Finally, Sunbelt Securities Inc. grew its holdings in Humana by 150.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 408 shares of the insurance provider's stock valued at $129,000 after buying an additional 245 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.